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Introduction
Systemic Lupus Erythematosus (SLE) is a chronic
inflammatory disease of unknown etiology. The evolu-
tion of the disease is unpredictable. Most patients follow
a chronic course and have flare-ups or exacerbations,
with a number of hospital admissions.
Hypothesis and objectives
The use of Rituximab (RTX) decrease the hospital
admissions in SLE patients refractory to immunosup-
pressive therapy.
Material and methods
This is an observational, retrospective and multicenter
study. Sequential observation was made at baseline, at
24
th week and final visit. The outcome variables were:
clinic improvement measured by SLEDAI, Physician’s
Global Assessment (PGA) and patient hospitalization for
SLE during the 24
th week and final visit. Statistical ana-
lysis of the qualitative and quantitative variables was
done by Chi-square and T-test/Wolcoxon, respectively.
Results
We treated 46 patients (94% women), mean age 36.50 ±
11.47 ages, 91% Caucasians.
Monitoring: mean of 21,1±13,9 months. The main rea-
son for use of RTX was: nephritis (24%,) arthritis (28%),
thrombocytopenia (11%), neurological (13%), cutaneous
(13%) and others (11%).
The most common dose used was 2x1g (87%). The
median of cycles was 2 (rank 1-3). Patients treated with
RTX improved SLEDAI, PGA and reduced hospital
admissions (table 1).
Conclusions
RTX may be effective in SLE patients refractory to
immunosuppressive therapy, as it gets to control disease
activity and reduces hospital admissions. For these rea-
sons, RTX should be considered a therapeutic option of
first choice in these patients.
Author details
1Rheumatology Unit, Valme University Hospital, Seville, Spain.
2Rheumatology
Unit, Malaga Civil Hospital, Malaga, Spain.
3Rheumatology Unit, Gregorio
Marañón University Hospital, Madrid, Spain.
Published: 25 November 2010
doi:10.1186/1479-5876-8-S1-P70
Cite this article as: Martínez-Pérez et al.: Rituximab reduces the
hospitalization in patients with systemic lupus erythematosus. Journal of
Translational Medicine 2010 8(Suppl 1):P70.
1Rheumatology Unit, Valme University Hospital, Seville, Spain
Full list of author information is available at the end of the article
Table 1 Endpoints
Baseline 24th week Final Visit
SLEDAI (0–105), median
(rank)
14.5 (7.8-22.3) 4.0 (2.0–6.0)** 2.0 (0.0–4.0)**
PGA (0–3), median (rank) 2.8 (2.0–3.0) 0.0 (0.0–1.0)** 0.0 (0.0-1.0)
Hospitalization, n (%) 25 (54%) 1 (2.3%)** 2 (4%)**
**p <0,0005 respect to baseline.
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